Clinical Trial Update: Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing icotinib after chemotherapy versus chemotherapy alone as adjuvant therapy in stage IIA-IIIA non-small cell lung cancer with an EGFR muta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Cancer | Phase 3 | Status: TERMINATED